Press coverage about Recro Pharma (NASDAQ:REPH) has been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Recro Pharma earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 47.3594773141333 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Recro Pharma (REPH) traded down $0.05 on Friday, hitting $9.65. The stock had a trading volume of 57,797 shares, compared to its average volume of 131,103. Recro Pharma has a one year low of $5.81 and a one year high of $10.59. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.35 and a current ratio of 1.59.
Several brokerages have recently issued reports on REPH. Piper Jaffray Companies reissued a “buy” rating and set a $11.00 price target on shares of Recro Pharma in a report on Friday, October 27th. Zacks Investment Research raised shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $8.25 price objective for the company in a report on Wednesday, August 16th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $11.65.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.